TP53 mutation is associated with a poor clinical outcome for non-small cell lung cancer: Evidence from a meta-analysis

• Published in: Molecular and clinical oncology Vol. 5; no. 6; pp. 705 - 713
• Main Authors: Gu, Jincui, Zhou, Yanbin, Huang, Lixia, Ou, Weijun, Wu, Jian, Li, Shaoli, Xu, Junwen, Feng, Jinlun, Liu, Baomo
• Format: Journal Article
• Language: English
• Published: England D.A. Spandidos 01.12.2016; Spandidos Publications; Spandidos Publications UK Ltd
• Subjects: Apoptosis; Cancer therapies; Care and treatment; Cell cycle; Clinical outcomes; Confidence intervals; Deoxyribonucleic acid; Development and progression; DNA; DNA repair; Gene mutations; Genetic aspects; Health aspects; Lung cancer; Lung cancer, Non-small cell; Medical prognosis; Meta-analysis; Mutation; non-small cell lung cancer; Oncology; prognosis; Proteins; Software; Studies; tumor protein 53 mutation; Tumor proteins; non-small cell lung cancer; prognosis; tumor protein 53 mutation
• ISSN: 2049-9450; 2049-9469
• DOI: 10.3892/mco.2016.1057

A number of studies have examined the association between tumor protein 53 (TP53) mutations and the clinical outcome in patients with non-small-cell lung cancer (NSCLC), although these have yielded conflicting results. In the present study, electronic databases updated to September 2015 were searched to find relevant studies. A meta-analysis was performed on the eligible studies, which quantitatively evaluated the association between the TP53 mutations and the survival of patients with NSCLC. Subgroup and sensitivity analyses were performed. A total of 19 studies that involved a total of 6,084 patients with NSCLC were included. When the TP53 mutation group (n=1,406) was compared with the wild-type group (lacking TP53 mutations; n=1,965), the wild-type group was associated with a significantly higher overall survival rate [hazard ratio (HR), 1.26; 95% confidence interval (CI) 1.12-1.41, P<0.0001]. Significant benefits of overall survival in the wild-type group were found in the subgroup involving patients with NSCLC in the early stages, including the I/II phases (HR, 1.93, 95% CI, 1.17-3.19, P=0.01; heterogeneity, I2=0.0%, P=0.976) and patients with adenocarcinoma (HR, 3.06; 95% CI, 1.66-5.62, P<0.0001; heterogeneity: I2=0.0%, P=0.976). This meta-analysis has indicated that TP53 gene alteration may be an indicator of a poor prognosis in patients with NSCLC. Furthermore, the results also suggested that the role of TP53 mutations may differ according to different pathological types and clinical stages. The presence of these mutations may define a subset of patients with NSCLC appropriate for investigational therapeutic strategies.